First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Yanli ZhuangCesar CalderonStanley J MarciniakEsther Bouman-ThioPhilippe SzaparyTong-Yuan YangAllen SchantzHugh M DavisHonghui ZhouZhenhua XuPublished in: European journal of clinical pharmacology (2016)
Guselkumab pharmacokinetic profiles were generally comparable between healthy subjects and patients with psoriasis. Guselkumab, administered as an IV infusion or SC injection, was well tolerated in healthy subjects and patients with psoriasis.